About
Drugs for metabolic disease
Areas of Focus
Categories
Small Molecule Pharmaceutical
Team (34)
Clinical Trials (14)
View allTotal Trials
14
As Lead Sponsor
14
As Collaborator
0
Total Enrollment
803
By Phase
PHASE2: 5PHASE1: 9
By Status
COMPLETED: 12WITHDRAWN: 2
Clinical Trials Pipeline14 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Today
Hover over trial bars to see details
Recent Trials
NCT05146284Lead Sponsor
Study to Assess PXL770 in Subjects With Adrenomyeloneuropathy (AMN) Form of X-linked Adrenoleukodystrophy (X-ALD or ALD)
PHASE2Withdrawn
Started: Sep 30, 2023 · Completed: Sep 30, 2024
NCT05200104Lead Sponsor
Study to Assess PXL065 in Subjects With Adrenomyeloneuropathy (AMN) Form of X-linked Adrenoleukodystrophy (X-ALD or ALD)
PHASE2Withdrawn
Started: Sep 30, 2023 · Completed: Sep 30, 2024
NCT05441904Lead Sponsor
Study to Assess the Safety, Tolerability, and Pharmacokinetics of PXL770 in Healthy Subjects.
PHASE1Completed
16 participants
Started: Mar 8, 2021 · Completed: Mar 29, 2021
NCT04321343Lead Sponsor
Study of PXL065 in Patients With Nonalcoholic Steatohepatitis (NASH)
PHASE2Completed
117 participants
Started: Sep 1, 2020 · Completed: Jun 20, 2022
NCT03950882Lead Sponsor
A Study to Assess the Pharmacokinetics of PXL770 After 4 Weeks of Treatment in Subjects With NAFLD
PHASE1Completed
17 participants
Started: Aug 1, 2019 · Completed: Mar 31, 2020
Locations (1)
Headquarters
Lyon, France
Map
Loading map...